Startup profile · funding coverage
Braveheart funding, valuation and investors
Late-clinical biotech developing HCM therapy BHB-1893 (Hengrui-partnered).
Keep track of Braveheart
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
$185M · November 2025
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$185M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a
Investors in latest funding
Other: Andreessen Horowitz
Overview
Braveheart Bio is a biotechnology company developing BHB-1893, a late-clinical-stage therapy for hypertrophic cardiomyopathy (HCM), in partnership with Hengrui Pharmaceuticals. In November 2025 Braveheart launched with a $185M Series A financing with participation from Andreessen Horowitz Bio + Health, Forbion, OrbiMed, Frazier Life Sciences, and Enavate Sciences. The company targets a large cardiovascular indication where several competitors pursue overlapping mechanisms. a16z's stake was notable enough to appear in public filing discussions around ownership percentages.
Why Braveheart is interesting
Crossover launch with $185M Series A for hypertrophic cardiomyopathy — a16z Bio + Health holds ~14% per IPO filing context; crowded cardio metabolic market.
Product & use cases
Clinical-stage biotech advancing BHB-1893 for HCM — partnered with Hengrui on development and commercial rights structure.
- Hypertrophic cardiomyopathy treatment development
- Late-clinical asset advancement toward registration trials
- Cardiovascular franchise build via partnered molecule
Key facts
- Launch (Nov 2025): $185M Series A with a16z Bio + Health (Braveheart press)
- Asset: BHB-1893 for HCM; Hengrui partnership
- Co-investors: Forbion, OrbiMed, Frazier Life Sciences, Enavate Sciences
Funding history (newest first)
Investors in our directory
Funds linked from Braveheart's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Large launch round and Hengrui partnership vs. smaller single-asset biotechs; a16z and crossover syndicate validation.
HCM became hot biotech territory after MyoKardia's success. Braveheart enters with partnered asset and $185M war chest. Clinical differentiation vs. aficamten and others will determine outcome — early stage with high execution risk typical of cardio metabolic biotech.
-
Cytokinetics (aficamten) direct
HCM drug development competitor in same indication.
-
Bristol Myers / MyoKardia legacy programs incumbent
Established cardio pharma with HCM interest.
-
Other HCM biotech entrants direct
Crowded HCM pipeline post-MyoKardia acquisition.
Notable stories
- Braveheart launched publicly in November 2025 with one of larger biotech Series A rounds of the year.
- a16z ownership ~14% cited in IPO filing context per directory research notes.
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Braveheart's financing or category context.
FAQs about Braveheart
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.